First National Trust CO Gilead Sciences, Inc. Transaction History

First National Trust CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 26, 2023	BUY	$77.31 - $88.08 $19,868 - $22,636	257 Added 10.21%	2,774 $230,000
Q4 2022 Feb 02, 2023	BUY	$62.32 - $89.47 $156,859 - $225,195	2,517 New	2,517 $216,000
Q2 2019 Jul 22, 2019	SELL	$61.87 - $69.38 $192,972 - $216,396	-3,119 Closed	0 $0
Q1 2019 Apr 25, 2019	BUY	$62.53 - $70.05 $195,031 - $218,485	3,119 New	3,119 $203,000
Q4 2018 Jan 28, 2019	SELL	$60.54 - $79.0 $245,550 - $320,424	-4,056 Closed	0 $0
Q3 2018 Oct 31, 2018	SELL	$71.28 - $78.92 $235,152 - $260,357	-3,299 Reduced 44.85%	4,056 $0
Q2 2018 Jul 30, 2018	SELL	$64.88 - $75.68 $271,003 - $316,115	-4,177 Reduced 36.22%	7,355 $521,000
Q1 2018 Apr 30, 2018	SELL	$72.84 - $88.8 $199,872 - $243,667	-2,744 Reduced 19.22%	11,532 $870,000
Q4 2017 Jan 17, 2018	SELL	$71.15 - $83.52 $169,977 - $199,529	-2,389 Reduced 14.34%	14,276 $1.02 Million
Q3 2017 Nov 06, 2017	SELL	$72.11 - $85.47 $162,896 - $193,076	-2,259 Reduced 11.94%	16,665 $1.35 Million
Q2 2017 Aug 07, 2017	BUY	N/A	18,924	18,924 $1.34 Million

1,942

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $117B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of First National Trust CO, based on Form 13F filings with the SEC.

Stay updated on First National Trust CO with notifications on news.